-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Shares Its Experience at the Pharmaceutical Quality Inspection and Testing Technology Conference
Category:
发布时间：2025-04-15
【概要描述】
From April 10 to 11, the 28th Conference on Pharmaceutical Quality Inspection and Testing Technologies was held in Shijiazhuang. Experts, scholars, and industry representatives from across the national pharmaceutical sector gathered to discuss cutting-edge developments in pharmaceutical quality control and inspection and testing technologies.
From April 10 to 11, the 28th Pharmaceutical Quality Inspection and Testing Technology Conference was held in Shijiazhuang. Experts, scholars, and industry representatives from across the national pharmaceutical sector gathered to discuss cutting-edge developments in pharmaceutical quality control and inspection and testing technologies.
As a key platform for exchange in the field of pharmaceutical quality management, this conference focuses on discussions surrounding the promulgation and implementation of the 2025 Edition of the Chinese Pharmacopoeia, quality control throughout the entire lifecycle of pharmaceutical products, and innovations in testing and inspection technologies. The aim is to advance the standardization and internationalization of pharmaceutical testing and inspection methodologies, help enterprises adapt to regulatory changes, and enhance the quality and safety of pharmaceutical products.
As a leading enterprise in the industry, Shijiazhuang Sihua Pharmaceutical Group participated in the conference’s technical exchanges and成果展示. Liu Qingping, the company’s head of quality and general manager of the Quality Management Center, delivered a presentation titled “Key Implementation Points for Quality Control Throughout the Pharmaceutical Lifecycle,” sharing the company’s practical experience in pharmaceutical quality control and engaging in in-depth discussions with attending experts on critical quality-testing technologies.
This conference is co-hosted by the Hebei Provincial Pharmaceutical Industry Association and the Beijing Zhonggong Pharmaceutical Research Institute, with technical support from the Hebei Provincial Institute for Drug and Medical Device Testing, and organized by the Beijing Zhonglun Industrial Microbiology Research Institute.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091